long term health effects of glp 1 Application nutrition interventions with GLP-1 based therapies: A narrative review of the challenges and solutions How GLP-1 Medications Reduce Heart

In the Phase 2 trial, the most common adverse events were gastrointestinal: nausea (up to 25.6% at higher doses), diarrhea (up to 22.0%), vomiting (up to 12.2%), and constipation (up to 11.0%)

Researchers studying peptide safety profiles note that the Aib modification has been used across multiple GLP-1 agonists because of its reliability and low immunogenicity

Individual results may vary, so always consult a healthcare professional before starting treatment

Clinical trial data shows pancreatitis incidence in semaglutide studies ranges from 0.1% to 0.3%comparable to or lower than rates in untreated obese populations